Your browser is no longer supported. Please, upgrade your browser.
Settings
ACRX AcelRx Pharmaceuticals, Inc. daily Stock Chart
ACRX [NASD]
AcelRx Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.61 Insider Own0.40% Shs Outstand45.30M Perf Week4.32%
Market Cap163.99M Forward P/E- EPS next Y-1.08 Insider Trans-67.59% Shs Float44.32M Perf Month11.73%
Income-27.60M PEG- EPS next Q-0.23 Inst Own68.10% Short Float9.33% Perf Quarter45.97%
Sales24.70M P/S6.64 EPS this Y28.30% Inst Trans2.06% Short Ratio9.89 Perf Half Y14.56%
Book/sh0.30 P/B12.07 EPS next Y-18.70% ROA-22.30% Target Price7.60 Perf Year6.47%
Cash/sh2.18 P/C1.66 EPS next 5Y- ROE-100.20% 52W Range2.40 - 5.88 Perf YTD-5.97%
Dividend- P/FCF- EPS past 5Y5.70% ROI-38.20% 52W High-38.44% Beta2.32
Dividend %- Quick Ratio5.00 Sales past 5Y- Gross Margin66.20% 52W Low50.83% ATR0.18
Employees36 Current Ratio5.00 Sales Q/Q136.80% Oper. Margin-70.40% RSI (14)59.65 Volatility4.32% 4.92%
OptionableYes Debt/Eq6.63 EPS Q/Q-22.00% Profit Margin- Rel Volume0.76 Prev Close3.68
ShortableYes LT Debt/Eq5.57 EarningsOct 27 AMC Payout- Avg Volume417.73K Price3.62
Recom2.20 SMA208.63% SMA508.13% SMA2006.26% Volume316,356 Change-1.63%
Sep-15-16Reiterated ROTH Capital Buy $11.25 → $15
Aug-05-16Downgrade Stifel Buy → Hold
Oct-30-15Upgrade Jefferies Hold → Buy
Oct-05-15Reiterated ROTH Capital Buy $8.50 → $10.50
Sep-02-15Initiated H.C. Wainwright Buy $8.50
Jul-10-15Resumed ROTH Capital Buy $7.50
May-06-15Reiterated Mizuho Neutral $5.50 → $3
May-05-15Reiterated RBC Capital Mkts Outperform $8 → $7
Mar-10-15Reiterated RBC Capital Mkts Outperform $12 → $8
Mar-09-15Downgrade Mizuho Buy → Neutral $14 → $5.59
Feb-26-15Upgrade Mizuho Neutral → Buy $6 → $14
Nov-06-14Downgrade Mizuho Buy → Neutral $15 → $6
Sep-26-14Downgrade ROTH Capital Buy → Neutral
Jul-28-14Reiterated RBC Capital Mkts Outperform $15 → $12
Jul-28-14Reiterated Mizuho Buy $20 → $15
Jul-28-14Downgrade Canaccord Genuity Buy → Hold
Apr-17-14Initiated Canaccord Genuity Buy $16
Jan-07-14Initiated RBC Capital Mkts Outperform $15
Dec-19-13Reiterated Mizuho Buy $18 → $20
Dec-17-13Reiterated MLV & Co Buy $15 → $16.50
Sep-22-16 04:01PM  Findings from AcelRx Pharmaceuticals' Phase 3 SAP301 Study of ARX-04 in Abdominoplasty Patients to be Presented at Plastic Surgery Meeting PR Newswire
07:00AM  AcelRx Pharmaceuticals to Present at the Ladenburg Thalmann 2016 Healthcare Conference PR Newswire
Sep-19-16 06:07AM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Sep-16-16 07:20AM  Has AcelRx Pharmaceuticals Hit a Home Run?
Sep-15-16 04:18PM  Here's Why AcelRx Pharmaceuticals (ACRX) Stock Gained Today +9.76%
12:56PM  McDonalds Corporation (MCD), AcelRx Pharmaceuticals Inc. (ACRX) & More: Heres Why These Stocks Are Trending Today at Insider Monkey
09:28AM  Stocks to Watch: Pandora, Aerie, AcelRx, Sarepta, Goodyear, Apogee, GE at The Wall Street Journal
07:52AM  1-AcelRx's opioid painkiller succeeds in key study
06:52AM  AcelRx pain drug found safe in high-risk patients in late-stage study
06:32AM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
06:30AM  AcelRx Reports Positive Results for ARX-04 (sufentanil sublingual tablet, 30 mcg), Including in Elderly Patients and Patients with Organ Impairment, in Third Phase 3 Registration Trial, SAP303 PR Newswire
Sep-14-16 04:01PM  AcelRx Pharmaceuticals to Announce Topline Results in Phase 3 Study of ARX-04 in Patients with Post-Operative Moderate-to-Severe Acute Pain PR Newswire
Aug-31-16 07:00AM  AcelRx Pharmaceuticals to Participate at Two Upcoming Investor Events in September PR Newswire
Aug-29-16 07:00AM  AcelRx Pharmaceuticals Presents Results from Phase 3 Study of ARX04 in the Emergency Department at the International Society for Burn Injuries PR Newswire
Aug-15-16 08:11AM  AcelRx Pharmaceuticals' ARX-04 Final Stage Study Meets Primary Endpoint
07:03AM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhib
07:00AM  AcelRx Pharmaceuticals' ARX-04 Phase 3 Trial Met its Primary Endpoint, Reduced Pain Intensity in ER Patients with Moderate-to-Severe Acute Pain PR Newswire
Aug-08-16 01:46PM  ETFs with exposure to AcelRx Pharmaceuticals, Inc. : August 8, 2016
Aug-05-16 12:06PM  AcelRx Pharmaceuticals, Inc. :ACRX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 5, 2016
Aug-04-16 01:04PM  ACELRX PHARMACEUTICALS INC Financials -5.32%
08:40AM  AcelRx Pharmaceuticals (ACRX) in Focus: Stock Jumps 5.3%
Aug-02-16 07:01AM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Aug-01-16 04:18PM  Edited Transcript of ACRX earnings conference call or presentation 28-Jul-16 8:30pm GMT
07:00AM  AcelRx Pharmaceuticals to Present Initial Results of Phase 3 Study of ARX04 at World Congress of Mountain & Wilderness Medicine PR Newswire
Jul-29-16 06:13AM  ACELRX PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report +17.86%
Jul-28-16 06:17PM  AcelRx Pharmaceuticals reports 2Q loss
04:30PM  AcelRx Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today
04:10PM  AcelRx Pharmaceuticals Provides Corporate Update and Reports Second Quarter and Six Months 2016 Financial Results PR Newswire
07:07AM  Q2 2016 AcelRx Pharmaceuticals Inc Earnings Release - After Market Close
Jul-26-16 07:00AM  AcelRx Pharmaceuticals to Hold Second Quarter Financial Results Conference Call and Webcast on Thursday, July 28th, 2016 PR Newswire
Jul-20-16 12:05PM  ETFs with exposure to AcelRx Pharmaceuticals, Inc. : July 20, 2016
Jul-08-16 06:09AM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Jul-06-16 07:00AM  AcelRx Pharmaceuticals to Present at Cantor Fitzgerald 2nd Annual Healthcare Conference PR Newswire
Jun-28-16 07:00AM  AcelRx Pharmaceuticals Completes Patient Enrollment in Remaining Phase 3 Studies of ARX-04 as a Potential Treatment of Moderate-to-Severe Acute Pain PR Newswire
Jun-27-16 07:00AM  AcelRx Pharmaceuticals Joins Russell 3000 and Russell 2000 Indexes PR Newswire
Jun-22-16 04:06PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -5.23%
Jun-21-16 04:32PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E
Jun-02-16 07:00AM  AcelRx Pharmaceuticals to Participate in Three Upcoming Healthcare Investor Events in June PR Newswire
May-26-16 07:00AM  AcelRx Pharmaceuticals Presents Results from Phase 3 Study of ARX04 following Ambulatory Abdominal Surgeries at Euroanaesthesia PR Newswire
May-24-16 07:00AM  New Study Reveals Cost of Initial IV Opioid Dose in the Emergency Department for the Treatment of Acute Pain Exceeds $140 PR Newswire
May-19-16 06:52PM  ETFs with exposure to AcelRx Pharmaceuticals, Inc. : May 19, 2016
May-17-16 01:46PM  AcelRx Pharmaceuticals, Inc. :ACRX-US: Earnings Analysis: Q1, 2016 By the Numbers
May-06-16 07:00AM  AcelRx Pharmaceuticals Presents Subgroup Analysis Demonstrating Positive Results of ARX04 by Type of Abdominal Surgery PR Newswire
May-04-16 07:00AM  AcelRx Pharmaceuticals to Present at Two Upcoming Investor Events in May PR Newswire
06:18AM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
May-03-16 01:16AM  Edited Transcript of ACRX earnings conference call or presentation 2-May-16 8:30pm GMT
May-02-16 05:16PM  ACELRX PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
04:53PM  AcelRx Pharmaceuticals reports 1Q loss
04:30PM  AcelRx Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today
04:01PM  AcelRx Pharmaceuticals Provides Corporate Update and Reports First Quarter 2016 Financial Results PR Newswire
07:07AM  Q1 2016 AcelRx Pharmaceuticals Inc Earnings Release - After Market Close CCBN
Apr-28-16 07:00AM  AcelRx Pharmaceuticals to Hold First Quarter Financial Results Conference Call and Webcast on Monday, May 2nd, 2016 PR Newswire
Apr-12-16 08:30AM  AcelRx Pharmaceuticals (ACRX): Strong Industry, Solid Earnings Estimate Revisions
Mar-31-16 06:16AM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Mar-30-16 06:23AM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers
Mar-29-16 04:00PM  AcelRx Pharmaceuticals Names Howard B. Rosen as Chief Executive Officer and Provides Update on Clinical Development Activities and Corporate Priorities for 2016 PR Newswire
Mar-25-16 07:00AM  AcelRx Publishes a Review of Hospital-Based Opioid Patient-Controlled Analgesia, Risks and Pharmacoeconomics PR Newswire
Mar-24-16 05:44PM  ETFs with exposure to AcelRx Pharmaceuticals, Inc. : March 24, 2016
Mar-14-16 04:44PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement
04:34PM  ETFs with exposure to AcelRx Pharmaceuticals, Inc. : March 14, 2016
10:38AM  AcelRx Pharmaceuticals, Inc. :ACRX-US: Earnings Analysis: Q4, 2015 By the Numbers
07:00AM  AcelRx Pharmaceuticals Advances ARX-04 into Extension Phase of Open-Label Phase 3 Emergency Room Study PR Newswire
Mar-09-16 06:07AM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Mar-07-16 11:56PM  Edited Transcript of ACRX earnings conference call or presentation 7-Mar-16 9:30pm GMT
05:07PM  ACELRX PHARMACEUTICALS INC Files SEC form 10-K, Annual Report
04:30PM  AcelRx Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today
04:19PM  AcelRx Pharmaceuticals reports 4Q loss
04:01PM  AcelRx Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2015 Financial Results PR Newswire
07:07AM  Q4 2015 AcelRx Pharmaceuticals Inc Earnings Release - After Market Close
07:00AM  AcelRx Pharmaceuticals Initiates Phase 3 Study of ARX-04 in Patients with Post-Operative Moderate-to-Severe Acute Pain PR Newswire
Mar-04-16 06:08AM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement
Mar-03-16 07:00AM  AcelRx Pharmaceuticals to Hold Annual 2015 Financial Results Conference Call and Webcast on Monday, March 7th, 2016. PR Newswire -5.80%
Mar-01-16 07:00AM  AcelRx Pharmaceuticals to Present at Two Upcoming Investor Events in March PR Newswire
Feb-25-16 10:15AM  4 Stocks That Are Starting To Attract Major Attention Today Accesswire
07:00AM  AcelRx Pharmaceuticals' Moderate-to-Severe Acute Pain Candidate ARX-04 Shows Improved Pain Scores in ER Patients in Interim Phase 3 Analysis PR Newswire
06:49AM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Feb-19-16 04:54PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers +6.63%
Feb-17-16 04:57PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex
Feb-11-16 07:00AM  AcelRx Pharmaceuticals Presents Phase 3 Results from ARX-04 Clinical Program at JAB Burn and Wound Care Symposium PR Newswire
Feb-03-16 07:00AM  AcelRx Pharmaceuticals to Present at Two Upcoming Investor Events in February PR Newswire
Jan-21-16 07:00AM  AcelRx Pharmaceuticals Announces Presentation of Phase 3 Sufentanil Sublingual 30 mcg Tablet (ARX-04) Data at the European Congress of Ambulatory Surgery PR Newswire +7.58%
Jan-11-16 10:04AM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosur -8.72%
Jan-10-16 07:00AM  AcelRx Pharmaceuticals Announces Anticipated 2016 Milestones PR Newswire
Jan-08-16 07:02AM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:00AM  AcelRx Completes Protocol Review with FDA and Plans to Initiate Phase 3 Open-Label Study (IAP312) for Zalviso in 1Q 2016 PR Newswire
Dec-23-15 07:00AM  AcelRx Pharmaceuticals Receives Notice of Eligibility for Centralized Review of ARX-04 from European Medicines Agency PR Newswire
Dec-14-15 01:50PM  AcelRx Tanks on Pre-NDA Results -20.39%
07:02AM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:00AM  AcelRx Pharmaceuticals Conducts Pre-NDA Meeting with U.S. Food and Drug Administration for ARX-04 PR Newswire
Dec-08-15 11:39AM  Should You Avoid AcelRx Pharmaceuticals Inc (ACRX)? at Insider Monkey
Nov-27-15 03:19PM  Abraxas Petroleum Corp. (AXAS): Are Hedge Funds Right About This Stock? at Insider Monkey
Nov-23-15 07:00AM  AcelRx Pharmaceuticals to Present at Piper Jaffray 27th Annual Healthcare Conference PR Newswire +7.06%
Nov-19-15 08:50AM  A Look at Equity Market Momentum - Research on Multi-Fineline Electronix, AcelRx Pharmaceuticals, CAI International and Peregrine Pharmaceuticals Accesswire
07:09AM  AcelRx Pharmaceuticals Announces Sublingual Sufentanil Data Presentation at the American Society of Regional Anesthesia and Pain Medicine Meeting
07:00AM  AcelRx Pharmaceuticals Announces Sublingual Sufentanil Data Presentation at the American Society of Regional Anesthesia and Pain Medicine Meeting PR Newswire
Nov-10-15 07:00AM  AcelRx Pharmaceuticals to Present at Jefferies 2015 Global Healthcare Conference PR Newswire
Nov-05-15 07:00AM  AcelRx Pharmaceuticals to Present at Credit Suisse 24th Annual Healthcare Conference PR Newswire -5.99%
Nov-04-15 07:00AM  AcelRx Pharmaceuticals Presents Data from Phase 3 Clinical Trials Evaluating the Safety and Efficacy of Zalviso in Obese Surgical Patients PR Newswire +7.08%
Nov-03-15 06:09AM  ACELRX PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
Nov-02-15 06:55AM  Where Opportunity is Found - Research on AcelRx Pharmaceuticals, Tandem Diabetes Care, Brightcove and SciQuest Accesswire +11.17%
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes therapies for the treatment of acute pain in the United States. The company's lead product candidates include ARX-04, a sufentanil sublingual tablet that is in Phase III clinical trials for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in medically supervised settings; and Zalviso, a sufentanil sublingual tablet system, which is in Phase III clinical trials for the treatment of moderate-to-severe acute pain in hospitalized adult patients. It is also developing ARX-03, a fixed-dose sufentanil/triazolam sublingual tablet, which has been completed Phase II clinical trial for mild sedation and pain relief during painful procedures. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PERCEPTIVE ADVISORS LLC10% OwnerSep 15Sale3.70392,8501,452,8115,602,910Sep 16 04:37 PM
EDWARDS MARK GDirectorMay 12Buy3.055,00015,250115,000May 12 06:40 PM
EDWARDS MARK GDirectorMay 11Buy3.155,00015,750110,000May 12 06:40 PM
EDWARDS MARK GDirectorMay 10Buy3.255,00016,250105,000May 12 06:40 PM
PERCEPTIVE ADVISORS LLC10% OwnerNov 18Sale5.3542,300226,1325,995,760Nov 19 04:15 PM
PERCEPTIVE ADVISORS LLC10% OwnerNov 17Sale5.36133,900717,4096,038,060Nov 19 04:15 PM
PERCEPTIVE ADVISORS LLC10% OwnerNov 06Sale4.4717,10076,3656,171,960Nov 09 04:30 PM
PERCEPTIVE ADVISORS LLC10% OwnerNov 05Sale4.6275,000346,2606,189,060Nov 09 04:30 PM